- Is IBS Genetic? What a Polygenic Risk Score Means, by the Research
- What IBS is, and why it is called a gut-brain disorder
- Is IBS genetic? Many small gene effects, not one gene
- How big is the risk? Turning scores into “out of 100”
- Testing: what a 23andMe IBS result does and does not mean
- Red flags: symptoms that should not be written off as “just IBS”
- Self-management and diet: what the evidence supports
- Treatment landscape: the ATLANTIS trial and approved IBS drugs
- Family, children, insurance and talking with relatives
- FAQ
- Summary
- References
Is IBS Genetic? What a Polygenic Risk Score Means, by the Research
This article is for educational purposes only. It does not replace medical care, diagnosis, or genetic counseling. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.
My mom has had IBS for decades, and my DNA report flagged it too. I keep wondering if I’m next.
That worry is very common, and it makes sense. A family history and a DNA report can shift the odds, but neither one decides your future. The sections below show what research can and cannot say.
If my result is a higher-likelihood one, can I even handle knowing that?
That is a fair question. Nobody has to make sense of a result alone. A primary care clinician can talk it through with you, and a genetic counselor can help if the family history raises other questions.
My wife and I have young kids. Will they get this too?
That is one of the most natural worries for a parent. Family patterns in IBS work differently from single-gene diseases, and a later section explains what that means for children.
OK, so what do I actually do with this result?
The sections ahead walk through the path: which symptoms need a clinician first, how a primary care visit works, and which treatments have trial evidence behind them.
Bottom line: Research shows that IBS is partly genetic, but no single gene causes it. The largest genetic study so far found six gene regions, mostly linked to the nervous system. Family and twin studies suggest that shared environment matters too. A DNA report can nudge the odds a little. It cannot diagnose IBS or rule it out. Warning signs such as rectal bleeding or weight loss need a clinician first, whatever the score says.
What you’ll learn
- What the research says about IBS genes, families and twins, in plain words
- How to turn a risk score into “out of 100” numbers that make sense
- Which symptoms should never be written off as “just IBS”
- Which treatments have trial evidence, and how US and Canadian drug status differs
What IBS is, and why it is called a gut-brain disorder
Is IBS a real condition, or just a sensitive stomach?
It is real. NIDDK describes IBS as a disorder of gut-brain interaction: repeated belly pain and bowel changes without visible damage, and studies suggest it affects about 12 out of 100 people in the US.
Irritable bowel syndrome (IBS) is a group of symptoms that happen together. The main ones are repeated belly pain and changes in bowel movements. People may have diarrhea, constipation, or both. The digestive tract shows no visible damage or disease.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) calls IBS a disorder of gut-brain interaction. That means the gut and the brain do not “talk” to each other in the usual way. Think of a smoke alarm that goes off when there is only a little steam. The alarm is real, but the house is not on fire.
IBS is common. Studies suggest that about 12 out of 100 people in the United States have it. Women are up to two times more likely than men to have IBS. People younger than 50 are also more likely to have it.
Doctors diagnose IBS from the pattern of symptoms. They use a set of rules called the Rome IV criteria. In short, belly pain must happen at least one day a week, on average. It must be linked to bowel movements or to a change in stool. Symptoms must be active in the last 3 months and must have started at least 6 months ago.
| IBS subtype | Main stool pattern on “bad” days |
|---|---|
| IBS-C | Mostly hard or lumpy stools (constipation) |
| IBS-D | Mostly loose or watery stools (diarrhea) |
| IBS-M | A mix of both |
| IBS-U | Does not fit the other groups |
Could my DNA report tell me which IBS type I have?
No. Under Rome IV, subtypes come from stool patterns on bad days, and a Rome IV review suggests a 14-day bowel diary to sort that out. Bringing a diary to your primary care clinician is a practical first step.
Subtypes are based on the Bristol stool scale, a chart of seven stool shapes. A 14-day bowel diary can help sort out the subtype. NIDDK notes that in most cases, doctors do not need tests to diagnose IBS. Tests mainly check for other health problems. A genetic report is never a diagnosis. If these symptoms sound familiar, a primary care clinician is the right first step.
Section recap: IBS is a common gut-brain disorder diagnosed from symptoms, not from a scan or a DNA test. About 12 out of 100 people in the US have it.
Is IBS genetic? Many small gene effects, not one gene
So is there one IBS gene I could have inherited from my mom?
That is a common assumption, but no. A 2021 genome-wide study of 53,400 people with IBS identified six gene regions, and IBS is polygenic, meaning many common variants each add a very small effect.
IBS is partly genetic. But it does not follow the rules of single-gene diseases. It is polygenic, meaning many common gene variants each add a very small effect.
The biggest study so far is a genome-wide association study, or GWAS. A GWAS scans the DNA of many people to find spots linked to a disease. This one, published in 2021, compared 53,400 people with IBS to 433,201 people without it. It then checked the results in a 23andMe group of 205,252 people with IBS. Some authors of the study work for 23andMe.
The study found six gene regions, called loci, linked to IBS.
| Gene region | What the study reported |
|---|---|
| NCAM1 | Linked to mood/anxiety or nervous system activity |
| CADM2 | Linked to mood/anxiety or nervous system activity |
| PHF2/FAM120A | Linked to mood/anxiety or nervous system activity |
| DOCK9 | Linked to mood/anxiety or nervous system activity |
| CKAP2/TPTE2P3 | Confirmed IBS signal |
| BAG6 | Confirmed IBS signal |
The first four regions are tied to mood and anxiety disorders, the nervous system, or both. The study also found a strong genetic overlap between IBS and anxiety, neuroticism and depression. This overlap is called a genetic correlation. Here it was above 0.5 on a scale where 1 is a perfect match. The authors said this points to shared biology. It does not suggest that anxiety simply causes gut symptoms.
Families and twins tell a mixed story. Studies of relatives show that IBS clusters in families. But they also show that shared homes and habits play a part.
| Study | What it found |
|---|---|
| Swedish family study, 2015 | Siblings, children and parents of people with IBS had higher odds. So did spouses, who share no genes |
| US twin study, 2001 | 17 out of 100 identical co-twins vs 8 out of 100 fraternal co-twins also had IBS |
| Norwegian twin study, 2006 | 22 out of 100 identical vs 9 out of 100 fraternal co-twins had IBS |
| Swedish adoption study, 2017 | A birth parent with IBS raised the odds. An adoptive parent with IBS did not, to a significant degree |
The 2021 GWAS also looked at family history. About 24 out of 100 people with IBS reported an affected relative. Among people without IBS, about 10 out of 100 did. The paper also notes that people with an affected relative are two to three times more likely to develop IBS. That sounds large. But “two to three times” is a relative number, so the next section turns it into absolute terms.
If home life matters too, who should I talk to about our family pattern?
Good question. A Swedish family study found higher odds in blood relatives and even in spouses, who share no genes, while a Swedish adoption study pointed to birth parents, not adoptive ones. A primary care clinician can review your family history, and a genetic counselor can help if it hints at something beyond IBS.
The Norwegian twin study found one more clue. Very low birth weight, under 1,500 grams, was linked to higher odds of IBS (OR 2.4). In that group, IBS also started about 7.7 years earlier. Early life, not only genes, seems to shape risk.
The 2001 twin study is older. Its authors said genes play a role, but that “social learning” has an equal or greater effect. In that study, having a parent with IBS was a stronger predictor than having a twin with IBS. The Swedish team made a similar point. Higher risk in spouses suggests a shared environment, not only shared genes.
A simple picture helps. Genes are like the slope of a hill. Stress, infections and daily life are like the rain. A steeper slope makes water run faster. But without rain, little happens. To talk about family patterns, a primary care clinician or a genetic counselor is a good place to start.
Section recap: IBS is polygenic. Six gene regions are linked to it, mostly on the gut-brain axis. Family studies show both genes and shared environment matter.
How big is the risk? Turning scores into “out of 100”
My report says higher than typical. Does that mean I will probably get IBS?
Not necessarily. Start from the NIDDK baseline of about 12 out of 100. In a UK Biobank study, a high versus low research risk score, not the 23andMe score, meant only a 12% higher rate, roughly 12 versus 13 out of 100 (illustrative).
Risk numbers can be confusing. Two words matter most. Relative risk compares two groups. Absolute risk tells you how many people out of 100 actually get the condition.
Start with the baseline. About 12 out of 100 people in the US have IBS. Every other number should be read against that starting point.
Odds ratios and hazard ratios. Studies often report an odds ratio (OR) or a hazard ratio (HR). Both compare one group to another. A value of 1.0 means no difference. A value of 2.0 means roughly double the odds or rate.
The table below applies study results to the US baseline of 12 out of 100. These are illustrative conversions only. Each study had its own baseline. They are not a personal risk estimate.
| Relationship or factor | Study result | Illustrative “out of 100” |
|---|---|---|
| No affected relative (US baseline) | — | about 12 out of 100 |
| Cousin with IBS | OR 1.11 | about 13 out of 100 |
| Spouse with IBS | OR 1.51 | about 17 out of 100 |
| Birth parent with IBS (adoptees) | OR 1.67 | about 18 to 19 out of 100 |
| Sibling with IBS | OR 1.75 | about 19 out of 100 |
| Parent with IBS (child’s view) | OR 1.82 | about 20 out of 100 |
| Child with IBS (parent’s view) | OR 1.90 | about 21 out of 100 |
| High vs low research polygenic score | HR 1.12 | about 13 out of 100 |
The last row is worth a closer look. A large UK Biobank study built its own polygenic risk score for IBS. A polygenic risk score adds up many small gene effects into one number. From here on, this article calls it a “risk score.”
People with a high risk score had only a 12% higher rate than people with a low one. On the US baseline, that is roughly 12 versus 13 out of 100 (illustrative). This research score is not the 23andMe score. No effect size for the 23andMe IBS report could be found.
Lifestyle showed a bigger link than the risk score in that study. An unfavorable lifestyle was linked to a 56% higher rate than a favorable one. Enough sleep was linked to a lower rate (HR 0.72). People with both a high risk score and an unfavorable lifestyle had an HR of 1.80. Over about 12 years, that is roughly 1.8 versus 3.2 out of 100 (illustrative).
These links are observational. They do not prove that lifestyle changes prevent IBS. The study also found no sign that lifestyle canceled out genetic risk.
Should I change my sleep or lifestyle because of this score?
That same UK Biobank study linked adequate sleep to a lower IBS rate, but the link was observational and does not prove prevention. Your primary care clinician can help you choose changes that fit your overall health.
Heritability is a different idea. Heritability is the share of differences across a whole population that is linked to genes. It is not a person’s chance of getting IBS.
| Heritability estimate | Source |
|---|---|
| 48.4% among women | Norwegian twin study |
| 19.5% | Swedish adoption study |
| 5.77% from common DNA variants | 2021 GWAS |
| 0% to 57% across twin studies | Range cited in the 2021 GWAS |
Why are these numbers so different? Each study used a different method and population. Twin studies compare identical and fraternal twins. Adoption studies compare birth and adoptive families. A GWAS counts only common DNA variants it can measure.
The wide range shows how hard IBS genetics is to pin down. A clinician can help put any risk number in context.
Section recap: Start from about 12 out of 100. Family history raises the odds modestly. A research risk score moved the odds only about 1 point out of 100 (illustrative).
Testing: what a 23andMe IBS result does and does not mean
Can I use my 23andMe result to get diagnosed?
No. NIDDK notes that in most cases doctors do not use tests to diagnose IBS at all; tests mainly check for other health problems. A polygenic report is a risk estimate, not a diagnosis.
There is no genetic test used to diagnose IBS. NIDDK says doctors usually do not use tests to diagnose IBS at all. Tests are used to check for other health problems.
23andMe offers an IBS report as part of its Health Predisposition reports. It is a polygenic report. According to the company’s clinician catalog, it looks at more than 27,000 variants. The catalog lists several ancestry groups for the report. These include European, East/Southeast Asian, South Asian, Hispanic/Latino and Sub-Saharan African/African American. The catalog gave no effect size or cut-off for the report.
| Question | 23andMe polygenic IBS report | Clinical workup by a clinician |
|---|---|---|
| What it measures | A sum of many small DNA effects | Symptoms, history, exam and targeted tests |
| Can it diagnose IBS? | No | Yes, using Rome IV criteria |
| Can it rule out other diseases? | No | Yes, that is its main job |
| Kind of result | A risk estimate only | A diagnosis or a referral |
What tests might a clinician order? Guidelines describe a short list. The American College of Gastroenterology (ACG) guideline supports a “positive” diagnosis based on symptoms. It suggests a celiac blood test and fecal calprotectin, a stool test for gut inflammation, when diarrhea is a main symptom. These help rule out celiac disease and inflammatory bowel disease (IBD).
British guidance gives a fuller primary-care list:
- A full blood count
- CRP or ESR, blood markers of inflammation
- A blood test for celiac disease
- Fecal calprotectin for people under 45 with diarrhea
The British guideline sees no role for colonoscopy unless there are warning signs or unusual diarrhea features.
What should I bring to my doctor, and which tests might they order?
Bring the report and a symptom history. The ACG guideline suggests a celiac blood test and fecal calprotectin when diarrhea is a main symptom, but your primary care clinician decides which tests fit you.
A note on vocabulary. A “variant of uncertain significance” is a term used for single-gene tests. It does not apply to a polygenic IBS report. A polygenic result is simply a nudge up or down in the odds. Bring the report to a primary care visit, and let the clinician decide which tests make sense.
Section recap: A 23andMe IBS report is a risk estimate, not a diagnosis. IBS is diagnosed from symptoms, with tests used to rule out other conditions.
Red flags: symptoms that should not be written off as “just IBS”
If my DNA says IBS is likely, can I just assume my symptoms are IBS?
Please don’t. NIDDK lists rectal bleeding, bloody or black stools, anemia and weight loss as signs that may point to another health problem. Those need a clinician soon, whatever a genetic report says.
A DNA score should never delay care. Some symptoms may point to a different problem. They call for a clinician visit soon, no matter what a genetic report says.
Warning signs listed by NIDDK:
- Bleeding from the rectum
- Bloody stools or black, tarry stools
- Anemia (low red blood cells)
- Weight loss
- A family history of celiac disease, colon cancer or IBD
More warning signs from a Rome IV review:
- Age over 50 without past colon cancer screening
- Passing stools during the night
- A recent change in bowel habits
- A lump in the belly or swollen lymph nodes
British guidance also flags severe watery diarrhea and diarrhea-type symptoms at age 50 or older. A clinician may use colonoscopy to check for colon cancer or IBD.
Think of a check-engine light. A risk score is like knowing a car model has a minor quirk. It does not tell you to ignore the light.
I’m in my late thirties with no warning signs. When should colon cancer screening come up?
The USPSTF recommends screening from age 45 for adults without symptoms. A Rome IV review lists a family history of colon cancer or IBD as a warning sign to check before diagnosing IBS, so raise any such history with your doctor.
Screening is a separate topic. The US Preventive Services Task Force (USPSTF) recommends colorectal cancer screening for all adults aged 50 to 75. It also recommends screening for adults aged 45 to 49. These rules are for people without symptoms. People with warning signs need a diagnostic workup now. They should not wait for a screening birthday.
Section recap: Bleeding, black stools, anemia, weight loss, night-time stools and similar signs need prompt evaluation. A genetic score changes none of that.
Self-management and diet: what the evidence supports
Is there anything I can do to keep IBS from starting, given my genes?
That is a hopeful question, but no study has shown a proven way to prevent it. Guidelines focus on managing symptoms; British guidance, for example, supports soluble fiber such as psyllium, started low.
No study has shown a way to prevent IBS in people with a high genetic risk. The goal is to manage symptoms. Several options have guideline support.
| Approach | What guidelines say |
|---|---|
| Low-FODMAP diet | ACG recommends a limited trial. British guidance calls it second-line, with a trained dietitian (weak recommendation) |
| Soluble fiber (psyllium) | British guidance says it helps overall symptoms and pain. Start low and build up slowly. Avoid insoluble fiber such as wheat bran |
| Gut-directed psychotherapy | ACG suggests it for overall symptoms. British guidance says IBS-specific CBT and gut-directed hypnotherapy may help |
| Activity, stress and sleep | NIDDK lists more physical activity, less stress and enough sleep |
| Antispasmodic medicines | NIDDK lists these among options for pain |
FODMAPs are a group of carbohydrates that gut bacteria ferment. A low-FODMAP plan cuts them for a while, then adds foods back based on how well they are tolerated. A dietitian can make this safer and less restrictive.
Why do talking therapies help a gut problem? The gene findings offer a clue. Several IBS gene regions sit on the gut-brain axis. So treatments that calm the nervous system make biological sense.
A 2019 review pooled 53 trials of antidepressants and psychological therapies. Both worked better than control. The review reported risk ratios for symptoms not improving:
| Treatment | Risk ratio (lower is better) | Illustrative “out of 100” |
|---|---|---|
| Antidepressants vs placebo | 0.66 | If 60 out of 100 stayed unwell on placebo, about 40 out of 100 would on an antidepressant |
| Psychological therapies vs control | 0.69 | If 60 out of 100 stayed unwell, about 41 out of 100 would with therapy |
The “out of 100” figures are illustrative. The placebo rate of 60 is an example, not a study number. CBT, relaxation, hypnotherapy and other talk therapies all helped when pooled. The authors warned that therapy effects “may be overestimated” because blinding was hard.
Would therapy really help a gut problem, and how would I even find someone?
A 2019 meta-analysis of 53 trials of antidepressants and psychological therapies found the therapies beat control, though the authors warned the effects may be overestimated. Your primary care clinician can refer you to a therapist or a dietitian.
Diet changes are a bit like adjusting a thermostat. Small, steady changes often work better than big swings. Ask a primary care clinician for a dietitian or therapist referral.
Section recap: Diet changes, soluble fiber and gut-directed therapies have guideline support. They manage symptoms; they do not erase genetic risk.
Treatment landscape: the ATLANTIS trial and approved IBS drugs
I heard an antidepressant gets used for IBS. Does that mean it’s all in my head?
Not at all. British guidance describes low-dose tricyclics as gut-brain neuromodulators. In the ATLANTIS trial, symptom scores improved modestly versus placebo, while more people stopped due to adverse events. It is off-label for IBS and prescriber-only.
Low-dose amitriptyline: the ATLANTIS trial
Amitriptyline is a tricyclic antidepressant (TCA), an older type of antidepressant. At low doses it is used as a “gut-brain neuromodulator.” That means it may calm pain signals between the gut and the brain.
ATLANTIS was a large phase 3 trial, published in The Lancet in 2023. Its authors called it the largest trial of a TCA in IBS ever done.
| ATLANTIS detail | Result |
|---|---|
| Setting | 55 general practices in England |
| People | 463 adults, mean age 48.5, 68% women |
| Who joined | Rome IV IBS, still bothered after diet changes and first-line treatment |
| What the trial used | 10 mg daily, adjusted over 3 weeks up to 30 mg, vs placebo, for 6 months |
| Main result | Symptom score 27.0 points lower than placebo at 6 months (difference -27.0; 95% CI -46.9 to -7.10) |
| Stopped due to adverse events | 13 out of 100 on amitriptyline vs 9 out of 100 on placebo |
The symptom score is the IBS Symptom Severity Score (IBS-SSS), a standard questionnaire. Lower scores mean milder symptoms. The trial had five serious adverse reactions in total: 2 on amitriptyline and 3 on placebo.
A 2025 follow-up looked at who benefited most. These subgroup findings are exploratory. They came from analyses planned after the trial ended.
- Age 50 or older: a larger symptom score benefit (46.5 points)
- Men, people with IBS-D, and people with higher PHQ-12 scores (a body symptom questionnaire) saw stronger effects
- Side effects were similar across almost all IBS subtypes
- The predictors were clinical and social, not genetic
Status and safety. Amitriptyline is not approved for IBS. In the US, its labels list depression only, so IBS use is off-label. In Canada, its labels list depressive illness only, so IBS use is off-label there too.
US labels carry a boxed warning about suicidal thoughts with antidepressants. Only a prescriber should start, change or stop it. This article gives no dosing advice. ATLANTIS took place in UK primary care. Results have not been tested in US or Canadian practice.
Drugs approved for IBS in the US and Canada
US gastroenterology guidelines from the American Gastroenterological Association (AGA) rate drugs by subtype. For IBS-C, AGA gave linaclotide a strong recommendation. It gave plecanatide, lubiprostone and tenapanor conditional ones. For IBS-D, AGA gave eluxadoline, rifaximin and alosetron conditional recommendations. ACG also recommends rifaximin for IBS-D.
Status differs by country. The table follows FDA and Health Canada records.
| Drug (subtype) | US status (FDA) | Canada status (Health Canada) |
|---|---|---|
| Linaclotide (IBS-C) | Linzess: IBS-C in adults and children 7+ | Constella: IBS-C in adults; marketed. Initial authorization 2013-12-02 |
| Plecanatide (IBS-C) | Trulance: IBS-C in adults | Trulance: IBS-C in adults; marketed since 2022 |
| Lubiprostone (IBS-C) | US only. Amitiza: IBS-C in women 18+ | Not available for IBS. Labeled only for chronic constipation; never marketed |
| Tenapanor (IBS-C) | US only. Ibsrela: IBS-C in adults; approved 2019-09-12 | Authorized 2020-04-15, but no longer marketed in Canada |
| Eluxadoline (IBS-D) | Viberzi: IBS-D in adults; approved 2015-05-27 | Viberzi: IBS-D in adults; marketed. Initial authorization 2017-01-26 |
| Rifaximin (IBS-D) | Xifaxan: IBS-D in adults | Zaxine: IBS-D in adults; marketed |
| Alosetron (IBS-D) | US only. Lotronex: only women with severe IBS-D; boxed warning | Not found in Health Canada’s drug database |
| Amitriptyline (any) | Off-label; labeled for depression only | Off-label; labeled for depressive illness only |
Lotronex carries a boxed warning for serious gut adverse reactions, such as ischemic colitis. NIDDK also lists laxatives and anti-diarrhea medicines as options. AGA advises against SSRIs for both subtypes, with low certainty.
Which IBS medicines are actually approved where I live?
It depends on country and subtype. FDA and Health Canada records differ; for example, lubiprostone and alosetron are available for IBS only in the US. A primary care clinician or gastroenterologist can match options to your subtype.
Choosing a drug is like choosing a key for a lock. The subtype decides which keys fit. A primary care clinician or gastroenterologist can match the drug to the subtype and to other health needs.
Section recap: Low-dose amitriptyline modestly improved symptoms in a large UK trial, but it is off-label in both countries. Subtype-based drugs differ between the US and Canada.
Family, children, insurance and talking with relatives
Should my brother and sister get tested now that I know my result?
That is a caring instinct. IBS has no single family variant to test, so cascade testing does not apply. A Swedish study found siblings had modestly higher odds, so sharing family history with their own clinicians is the practical step.
Cascade testing does not apply to IBS. Cascade testing means testing relatives for one known family variant. That works for single-gene diseases. IBS has no single family variant to test. Sharing family history with each relative’s clinician is the practical step.
What about children? A parent’s risk score does not predict a child’s future. Research shows that children of people with IBS have higher odds, about 20 out of 100 (illustrative) instead of 12.
So most children of a parent with IBS would not be expected to develop it. Twin and spouse studies suggest that home life matters as well. No source in this review recommends genetic testing of children for IBS. Ongoing belly pain in a child should be checked by a pediatrician.
Insurance and jobs in the US. The Genetic Information Nondiscrimination Act of 2008 (GINA) offers key protections.
| GINA covers | GINA does not cover |
|---|---|
| Health insurance | Life insurance |
| Employment | Disability insurance |
| Long-term care insurance | |
| Employers with fewer than 15 workers | |
| The US military |
Some states have extra laws. The Affordable Care Act also stops health insurers from refusing coverage for pre-existing conditions.
Protections in Canada. The Genetic Non-Discrimination Act became law in 2017. It bans requiring a genetic test before providing goods, services or a contract. It also bans requiring someone to share test results for those purposes. A “genetic test” here means an analysis of DNA, RNA or chromosomes, such as for disease prediction.
Could this result hurt my life insurance, and do I need a genetic counselor?
In the US, GINA protects health insurance and most jobs, but not life or disability insurance; Canada’s Genetic Non-Discrimination Act bars requiring genetic test results for contracts. ABGC-certified counselors, found through the NSGC.org directory, can help, especially if several relatives had colon cancer.
Talking with relatives. Sharing a result is a personal choice. A simple message can work: “IBS runs in the family, so mention it to your doctor.” It is like passing on a family recipe. It is useful context, not a fixed outcome.
Is genetic counseling needed? For a polygenic IBS score, usually not. It can help if a family history suggests a single-gene condition, such as several relatives with colon cancer. Genetic counselors in the US are certified by the American Board of Genetic Counseling (ABGC). The National Society of Genetic Counselors (NSGC) is the professional society, not the certifying body. Its directory at NSGC.org can help find a counselor.
Section recap: IBS has no cascade test, and children’s risk is only modestly higher. GINA protects health insurance and jobs in the US, but not life or disability insurance.
FAQ
Does a high IBS score mean IBS is certain?
No. A polygenic score is a probability estimate, not a diagnosis. IBS is diagnosed from symptoms using the Rome IV criteria. A research risk score moved the odds only slightly, from about 12 to 13 out of 100 (illustrative). Many people with a high score never develop IBS.
Will children inherit IBS from a parent?
Not in a simple way. Children of a parent with IBS have higher odds, about 20 out of 100 (illustrative) instead of 12. Shared home life also plays a role. No genetic test is used for children. A pediatrician can check ongoing symptoms.
Could an IBS genetic result affect health or life insurance?
In the US, GINA protects against genetic discrimination in health insurance and jobs. It does not cover life, disability or long-term care insurance. In Canada, the Genetic Non-Discrimination Act bans requiring genetic tests or results for contracts and services.
Can an employer find out about a genetic result?
In the US, GINA protects against genetic discrimination in employment. It does not apply to employers with fewer than 15 workers or to the military. Canada’s law bans requiring test results as a condition of a contract.
Is a second opinion worth getting?
It can be. A gastroenterologist can help if symptoms do not improve or the diagnosis feels unclear. Warning signs, such as bleeding or weight loss, call for prompt evaluation. A second opinion is a normal part of care.
Summary
- IBS affects about 12 out of 100 people in the US. It is diagnosed from symptoms, not from DNA.
- IBS is polygenic. Six gene regions are linked to it, mostly on the gut-brain axis.
- Family history raises the odds modestly. Shared environment matters too.
- A research risk score shifted the odds by about 1 out of 100 (illustrative). The 23andMe score has no published effect size.
- Bleeding, black stools, anemia, weight loss or night-time stools need prompt care.
- Diet, soluble fiber and gut-directed therapies have guideline support.
- Low-dose amitriptyline helped in the ATLANTIS trial. It is off-label in both countries.
- GINA protects health insurance and jobs, but not life insurance.
Related: Genetic Diseases category
This article is for educational purposes only. It does not replace medical care, diagnosis, or genetic counseling. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.
References
- NIDDK, National Institutes of Health. Definition & Facts, Diagnosis, and Treatment for Irritable Bowel Syndrome. https://www.niddk.nih.gov/health-information/digestive-diseases/irritable-bowel-syndrome/definition-facts
- Eijsbouts C, Zheng T, Kennedy NA, Bonfiglio F, et al. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nat Genet. 2021;53(11):1543-1552. https://pubmed.ncbi.nlm.nih.gov/34741163/
- Waehrens R, Ohlsson H, Sundquist J, Sundquist K, Zoller B. Risk of irritable bowel syndrome in first-degree, second-degree and third-degree relatives of affected individuals: a nationwide family study in Sweden. Gut. 2015;64(2):215-221. https://pubmed.ncbi.nlm.nih.gov/24694578/
- Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology. 2001;121(4):799-804. https://pubmed.ncbi.nlm.nih.gov/11606493/
- Bengtson MB, Ronning T, Vatn MH, Harris JR. Irritable bowel syndrome in twins: genes and environment. Gut. 2006;55(12):1754-1759. https://pubmed.ncbi.nlm.nih.gov/17008364/
- Waehrens R, Zoller B, Sundquist J, Sundquist K, Pirouzifard M. A Swedish national adoption study of risk of irritable bowel syndrome (IBS). BMJ Open Gastroenterol. 2017;4(1):e000156. https://pubmed.ncbi.nlm.nih.gov/29119001/
- Ying J, Ye D, Luo P, et al. Lifestyle and genetic predisposition are associated with incident irritable bowel syndrome: a population-based prospective cohort study. Clin Nutr. 2024;43(6):1544-1550. https://pubmed.ncbi.nlm.nih.gov/38754306/
- Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel Disorders (Rome IV). Gastroenterology. 2016. PMID 27144627. https://pubmed.ncbi.nlm.nih.gov/27144627/
- Lacy BE, Patel NK. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J Clin Med. 2017;6(11):99. https://pubmed.ncbi.nlm.nih.gov/29072609/
- Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17-44. https://pubmed.ncbi.nlm.nih.gov/33315591/
- Lembo A, Sultan S, Chang L, et al. AGA Clinical Practice Guideline on the Pharmacological Management of IBS With Diarrhea. Gastroenterology. 2022;163(1):137-151. https://pubmed.ncbi.nlm.nih.gov/35738725/ ; Chang L, Sultan S, Lembo A, et al. AGA Clinical Practice Guideline on the Pharmacological Management of IBS With Constipation. Gastroenterology. 2022;163(1):118-136. https://pubmed.ncbi.nlm.nih.gov/35738724/
- Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-1240. https://gut.bmj.com/content/70/7/1214
- Ford AC, Lacy BE, Harris LA, Quigley EMM, Moayyedi P. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. Am J Gastroenterol. 2019;114(1):21-39. https://pubmed.ncbi.nlm.nih.gov/30177784/
- Ford AC, Wright-Hughes A, Alderson SL, et al.; ATLANTIS trialists. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS). Lancet. 2023;402(10414):1773-1785. https://pubmed.ncbi.nlm.nih.gov/37858323/
- Wright-Hughes A, Ow PL, Alderson SL, et al. Predictors of response to low-dose amitriptyline for irritable bowel syndrome and efficacy and tolerability according to subtype: post hoc analyses from the ATLANTIS trial. Gut. 2025;74(5):728-739. https://pubmed.ncbi.nlm.nih.gov/39863398/
- U.S. Food and Drug Administration. Drugs@FDA and FDA prescribing labels (amitriptyline, Linzess, Amitiza, Trulance, Ibsrela, Lotronex, Viberzi, Xifaxan). https://www.accessdata.fda.gov/scripts/cder/daf/
- Health Canada. Drug Product Database and product monographs (Constella, Trulance, Viberzi, Zaxine, Ibsrela, Amitiza, amitriptyline). https://health-products.canada.ca/dpd-bdpp/
- U.S. Preventive Services Task Force. Colorectal Cancer: Screening. Final Recommendation Statement, May 18, 2021. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening
- National Human Genome Research Institute. Genetic Discrimination. https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
- Government of Canada, Justice Laws Website. Genetic Non-Discrimination Act, S.C. 2017, c. 3. https://laws-lois.justice.gc.ca/eng/acts/G-2.5/FullText.html
- 23andMe. Genetic Reports for Clinicians: Health Predispositions. https://www.23andme.org/clinicians/genetic-reports/health-predispositions/
Last updated: 2026-10-12
Author: Yu Mizuno (Editor-in-Chief, non-physician), GeneLumen editorial team. This article aggregates 21 sources. Of these, 13 are tier 1, 7 are tier 2 and 1 is a company source. They include NIDDK at the NIH, the US FDA, Health Canada and the USPSTF. They also include ACG, AGA and British gastroenterology guidelines, plus PubMed-indexed studies.
This article is for educational purposes only. It is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911.
🇯🇵 For readers in Japan — a separate Japanese edition written for Japan’s healthcare system (not a translation): https://genelumen.com/ja/ja-genetic-diseases/irritable-bowel-syndrome-genetic-risk
